Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.
What's in the News
- Christopher (Chris) Hill has been appointed as Chief Executive Officer and Director, succeeding Adrian Rawcliffe as part of company restructuring. Hill will also continue to serve as CFO. (Key Developments)
- The company has voluntarily filed a Form 15 to deregister its American Depositary Shares from the Securities Exchange Act of 1934. (Key Developments)
- Adaptimmune Therapeutics was removed from the Nasdaq Composite Index and the S&P Global BMI Index. (Key Developments)
- The company received notices from Nasdaq regarding non-compliance with market value and minimum bid price listing requirements, with deadlines set for December 1, 2025, and March 10, 2026, to regain compliance. (Key Developments)
Valuation Changes
- Fair Value: Remains unchanged at $1.50.
- Discount Rate: Essentially steady and holding at approximately 13.46%.
- Revenue Growth: No notable change and remains near 44.8%.
- Net Profit Margin: Increased slightly from 15.79% to 16.03%.
- Future P/E: Declined marginally from 20.29x to 19.98x.
Have other thoughts on Adaptimmune Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.